Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...

3 Mid-Sized Stocks to Consider This Season

As the festive season approaches, mid-cap stocks often present overlooked opportunities for investors seeking growth and stability in their portfolios. This asset class combines the agility of smaller firms with the reliability of established players, making them an ...

Brianne Gardner's 2025 stock picks

As you will see in the full video above, Brianne Gardner , senior wealth manager at Velocity Investments, Raymond James Canada reviews her past picks from September to see if they are on the money and she gives three new diversified picks for 2025 in healthcare, ener...

Buzz on the Bullboards: Three engaging TSX stocks with a holiday flavour

TSX this week The TSX has experienced a rocky week, marked by five consecutive sessions of declines. This downturn coincided with the unexpected resignation of Canada’s Finance Minister , Chrystia Freeland, just hours before she was scheduled to pre...

Critical materials crisis: Diversifying away from China’s monopoly

Author: Jesse Day, Commodity Culture CEO of Leading Edge Materials (TSXV:LEM / OTCQB:LEMIF) Kurt Budge points out China’s dominance in the production and export of critical raw materials such as graphite and rare earths, and why this is a growing...

Morning Market Outlook for Dec. 17, 2024

Stephen Whiteside of TheUpTrend.com considers recent moves in UnitedHealth Group, American Airlines, Avis Budget Group, Eversource Energy, Rogers, BCE, Bitfarms, BlackBerry, Super Micro Computer and other top-traded stocks in Tuesday’s Morning Market Out...

dynaCERT: Growth Rocket 2025 – Why It’s in the Spotlight

As 2024 draws to a close, it is worth considering new investments for the future. A successful investment in the technology sector requires a sound strategy, thorough research, and an understanding of the ins and outs of the industry. We have summarized key points for in...

In conversation with: Pierre Gratton: How can we built more mines faster in Canada?

The Mining Association of Canada’s President and CEO Pierre Gratton discusses his Vancouver Board of Trade presentation addressing the question, “How can we build more mines faster? He covers several key issues including, the need for critical miner...

Buzz on the Bullboards: Feeling holiday blues, or celebrating blue chip stocks?

Are you anticipating a calm market as the holidays approach? Think again. Astute investors and brokers recognize that this is their moment to excel. With the global economy constantly shifting, staying active is the smart move. Over the past week, some shareholde...

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
1 2 3 4 5 6 7 8 9 10 ...